|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:activities
|
complement inhibition
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
|
|
gptkbp:clinical_trial
|
Phase 3
chronic treatment
ALX N1210-HUS-301
ALX N1210-HUS-302
ALX N1210-PNH-301
ALX N1210-PNH-302
|
|
gptkbp:contraindication
|
active infection
|
|
gptkbp:developed_by
|
gptkb:Alexion_Pharmaceuticals
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
gptkbp:financial_performance
|
24 months
|
|
gptkbp:formulation
|
lyophilized powder
|
|
gptkbp:frequency
|
every 8 weeks
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Ravulizumab
|
|
gptkbp:indication
|
gptkb:Atypical_Hemolytic_Uremic_Syndrome
|
|
gptkbp:ingredients
|
Ravulizumab-cwvz
|
|
gptkbp:interacts_with
|
immunosuppressants
live vaccines
|
|
gptkbp:is_compared_to
|
gptkb:Eculizumab
|
|
gptkbp:is_monitored_by
|
renal function
hemoglobin levels
complement levels
|
|
gptkbp:is_used_for
|
treatment of paroxysmal nocturnal hemoglobinuria
|
|
gptkbp:manager
|
intravenous
bolus injection
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Japan
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
long half-life
inhibition of complement system
|
|
gptkbp:population
|
adults
pediatric patients
|
|
gptkbp:provides_information_on
|
PNH treatment guidelines
a HUS treatment guidelines
|
|
gptkbp:research_focus
|
rare diseases
kidney diseases
autoimmune disorders
complement-mediated diseases
hematological conditions
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
headache
nausea
abdominal pain
diarrhea
thrombosis
serious infections
hypersensitivity reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
C5 protein
|
|
gptkbp:traded_on
|
gptkb:Ultomiris
|
|
gptkbp:bfsParent
|
gptkb:Alexion_Pharmaceuticals,_Inc.
|
|
gptkbp:bfsLayer
|
6
|